Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive
You may also be interested in...
California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China
BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments
California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China
BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China